ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Shingles; Herpes Zoster

Treatments: Biological: ZOSTAVAX™

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01600079

8003.016 (Other Identifier)

V211-024

Details and patient eligibility

About

This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.

Enrollment: 1,505,647 patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Participants with continuous Kaiser Permanente Northern California (KPNC) membership since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment in KPNC before their study start date

Exclusion Criteria:

Trial design

1,505,647 participants in 2 patient groups

Vaccinated Cohort

Description:

Participants vaccinated with at least one dose of ZOSTAVAX™

Treatment:

Biological: ZOSTAVAX™

Unvaccinated Comparison Cohort

Description:

Participants who are not yet vaccinated with any zoster vaccine